Phospho-valproic acid for pancreatic cancer prevention
Phospho-valproic acid for pancreatic cancer prevention
批准号:
8090488
负责人:
Basil Rigas
金额:
$31.6万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-01 至 2015-04-30
关键词:
Animal ModelAnimalsAnticonvulsantsAreaCancer ControlCancer EtiologyCancer cell lineChemopreventionChemopreventive AgentCimetidineClinicalComplexDataDevelopmentGrowthHistone DeacetylationHumanIn VitroMalignant NeoplasmsMalignant neoplasm of pancreasMediatingMetabolismNew AgentsPathway interactionsPre-Clinical ModelPreventionPropertyProtocols documentationSTAT3 geneSafetySignal TransductionSignaling MoleculeTestingToxic effectTumor VolumeValproic AcidWorkXenograft Modelcancer preventiongenotoxicityin vivoinhibitor/antagonistmortalitynoveloverexpressionpancreatic cancer cellspancreatic neoplasmpreventpublic health relevance
中文摘要
描述(由申请人提供):令人印象深刻的证据支持化学预防有可能成为控制癌症(包括胰腺癌,最致命的癌症之一)的主要组成部分的观点。我们建议研究磷酸-丙戊酸(P-V),一种新的丙戊酸衍生物,作为胰腺癌的预防剂。P-V抑制人类癌细胞系生长的效力是VPA的245倍。在动物模型中,P-V对胰腺癌的有效性是VPA的两倍。例如,在异种移植模型中,与对照相比,P-V使肿瘤体积减少68%,而VPA使其减少34%(化学预防方案)。值得注意的是,当与临床上可用的抗溃疡化合物西咪替丁联合给药时,P-V在相同的动物模型中预防了100%的胰腺肿瘤。遗传毒性和动物毒性研究表明,P-V似乎是安全的。它的作用机制很复杂,涉及几个信号级联,最突出的是STAT 3。我们的假设是P-V1西咪替丁是一种有效和安全的胰腺癌化学预防剂,主要通过STAT 3途径起作用。为了检验这一假设,我们将追求以下具体目标:具体目标#1:确定P-V 1西咪替丁在胰腺癌临床前模型中的化学预防功效;具体目标#2:确定P-V 1西咪替丁在体外和体内的作用机制;具体目标#3:测定P-V1西咪替丁在培养胰腺癌细胞和动物体内的代谢及其在动物体内的安全性。在这些研究完成后,我们预计已经确定了一种有前途的新药物及其与西咪替丁组合的关键药理学参数。鉴于胰腺癌的重要性和缺乏有效的药物来对抗它,我们相信,拟议的工作有望在这一领域取得重大进展。
公共卫生相关性:大量令人印象深刻的证据支持这样一种观点,即化学预防有可能成为控制癌症的主要组成部分,包括胰腺癌,这是最致命的癌症之一。我们建议研究磷酸-丙戊酸(P-V),一种新的丙戊酸衍生物,作为胰腺癌的预防剂。鉴于胰腺癌的重要性和缺乏有效的药物来对抗它,我们相信,拟议的工作有望在这一领域取得重大进展。
英文摘要
DESCRIPTION (provided by applicant): An impressive body of evidence supports the notion that chemoprevention has the potential to be a major component of control of cancer, including pancreatic cancer, one of the most lethal cancers. We propose to study phospho-valproic acid (P-V), a novel derivative of valproic acid, as an agent for the prevention of pancreatic cancer. P-V inhibits the growth of human cancer cell lines up to 245-fold more potently than VPA. In animal models, P-V is twice as effective against pancreatic cancer as VPA. For example, in xenograft models P-V reduced tumor volume by 68%, compared to control, whereas VPA reduced it by 34% (chemoprevention protocol). Remarkably, when given in combination with cimetidine, a clinically available antiulcer compound, P-V prevented 100% of pancreatic tumors in the same animal model. P-V appears to be safe, as shown by genotoxicity and animal toxicity studies. Its mechanism of action is complex, involving several signaling cascades, most prominently STAT3. Our hypothesis is that P-V 1 cimetidine is an effective and safe chemopreventive agent against pancreatic cancer, acting primarily through the STAT3 pathway. To test this hypothesis, we will pursue the following specific aims: Specific Aim # 1: Determine the chemopreventive efficacy of P-V 1 cimetidine in preclinical models of pancreatic cancer; Specific Aim # 2: Determine the mechanism of action of P-V 1 cimetidine in vitro and in vivo; Specific Aim # 3: Determine the metabolism of P-V 1 cimetidine in cultured pancreatic cancer cells and animals and its safety in animals. At the completion of these studies, we expect to have determined key pharmacological parameters of a promising novel agent and its combination with cimetidine. Given the importance of pancreatic cancer and the lack of effective agents against it, we believe that the proposed work holds the promise of a significant advance in this area.
PUBLIC HEALTH RELEVANCE: An impressive body of evidence supports the notion that chemoprevention has the potential to be a major component of control of cancer, including pancreatic cancer, one of the most lethal cancers. We propose to study phospho-valproic acid (P-V), a novel derivative of valproic acid, as an agent for the prevention of pancreatic cancer. Given the importance of pancreatic cancer and the lack of effective agents against it, we believe that the proposed work holds the promise of a significant advance in this area.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phosphosulindac for dry eye
-
批准号:9907964
-
项目类别:
-
资助金额:$37.71万
-
财政年份:2020
-
负责人:Basil Rigas
-
依托单位:
Phospho-sulindac for Lung Cancer Treatment
-
批准号:9754402
-
项目类别:
-
资助金额:$6.72万
-
财政年份:2018
-
负责人:Basil Rigas
-
依托单位:
Phospho-sulindac for Lung Cancer Treatment
-
批准号:9333087
-
项目类别:
-
资助金额:$34.61万
-
财政年份:2014
-
负责人:Basil Rigas
-
依托单位:
Phospho-sulindac for Lung Cancer Treatment
-
批准号:8683477
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2014
-
负责人:Basil Rigas
-
依托单位:
Phospho-sulindac for Lung Cancer Treatment
-
批准号:8895867
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2014
-
负责人:Basil Rigas
-
依托单位:
MDC-1231 for cancer prevention
-
批准号:8547784
-
项目类别:
-
资助金额:$102.28万
-
财政年份:2012
-
负责人:Basil Rigas
-
依托单位:
MDC-1231 for cancer prevention
-
批准号:8257195
-
项目类别:
-
资助金额:$73.95万
-
财政年份:2012
-
负责人:Basil Rigas
-
依托单位:
Phospho-valproic acid for pancreatic cancer prevention
-
批准号:8465133
-
项目类别:
-
资助金额:$29.7万
-
财政年份:2010
-
负责人:Basil Rigas
-
依托单位:
MDC-1231 for cancer prevention
-
批准号:7999694
-
项目类别:
-
资助金额:$18.75万
-
财政年份:2010
-
负责人:Basil Rigas
-
依托单位:
Phospho-valproic acid for pancreatic cancer prevention
-
批准号:8256622
-
项目类别:
-
资助金额:$31.6万
-
财政年份:2010
-
负责人:Basil Rigas
-
依托单位:
Colon Cancer Prevention with Phospho-Sulindac
-
批准号:8215888
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2009
-
负责人:Basil Rigas
-
依托单位:
Colon Cancer Prevention with Phospho-Sulindac
-
批准号:7652010
-
项目类别:
-
资助金额:$32.21万
-
财政年份:2009
-
负责人:Basil Rigas
-
依托单位:
Colon Cancer Prevention with Phospho-Sulindac
-
批准号:8450053
-
项目类别:
-
资助金额:$29.56万
-
财政年份:2009
-
负责人:Basil Rigas
-
依托单位:
Colon Cancer Prevention with Phospho-Sulindac
-
批准号:8019490
-
项目类别:
-
资助金额:$31.44万
-
财政年份:2009
-
负责人:Basil Rigas
-
依托单位:
PHASE 1 DOSE SAFETY, PHARMACOKENETIC AND PHARMACODYNAMIC CLINICAL STUDY
-
批准号:7607870
-
项目类别:
-
资助金额:$0.74万
-
财政年份:2007
-
负责人:Basil Rigas
-
依托单位:
PHASE I, MULTIPLE-DOSE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC CLINICAL STUDY
-
批准号:7375369
-
项目类别:
-
资助金额:$0.69万
-
财政年份:2005
-
负责人:Basil Rigas
-
依托单位:
Pancreatic cancer prevention with NO-releasing NSAIDs
-
批准号:6952717
-
项目类别:
-
资助金额:$26.12万
-
财政年份:2004
-
负责人:Basil Rigas
-
依托单位:
Pancreatic cancer prevention with NO-releasing NSAIDs
-
批准号:7274307
-
项目类别:
-
资助金额:$24.93万
-
财政年份:2004
-
负责人:Basil Rigas
-
依托单位:
Pancreatic cancer prevention with NO-releasing NSAIDs
-
批准号:7123327
-
项目类别:
-
资助金额:$25.68万
-
财政年份:2004
-
负责人:Basil Rigas
-
依托单位:
Pancreatic cancer prevention with NO-releasing NSAIDs
-
批准号:7460856
-
项目类别:
-
资助金额:$24.93万
-
财政年份:2004
-
负责人:Basil Rigas
-
依托单位:
海外基金